Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The true burden of HHV-8 in solid organ transplant (SOT) setting remains difficult to quantify and there are several uncertainties about the best prevention and management of HHV-8 related complications.
Objectives: To describe epidemiology and impact on outcome of HHV-8 related diseases in patients undergoing SOT, we reviewed all episodes diagnosed at our hospital over 8-year period and performed a narrative systematic literature review.
Sources: A search on PubMed, Scopus and Cochrane Library, according to Preferred Reporting Items for Systematic Review and Meta-Analyses guidelines, was done. All types of studies, published in any language from January 2000 to January 2025, focused on HHV-8 related diseases in adult and paediatric SOT recipients were considered. Due to heterogeneity among studies, the evidence synthesis was descriptive.
Content: Ninety-one studies conducted across 26 countries were included. Overall, 337 HHV-8 cases were reported among 19,283 transplant recipients, including 215 (63.8%) kidney, 80 (23.7%) liver, 22 (6.5%) lung, 13 (3.9%) heart and 5 (1.5%) combined transplants. Considering only cohort studies, a prevalence of 1.1% was estimated. The median time from transplant to disease was 11 months. For cases with available data, mismatch D+/R- was common (41/63, 65.1%). Main diseases included cutaneous Kaposi Sarcoma (KS) (49.7%) and visceral KS (33.4%), Kaposi Sarcoma Inflammatory Cytokine Syndrome (KICS) accounted for 4.7%. Management of immunosuppressive regimens mostly consisted in in reduction of maintenance regimen (169/209, 80.9%) and switch from tacrolimus to mTOR (79/209, 37.9%). Twenty-five studies reported antiviral use in 48/70 (68.6%) patients consisting in ganciclovir/valganciclovir (21 cases), foscarnet (17 cases) and/or cidofovir (10 cases). Rituximab was used for both oncological and non-oncological HHV-8 related diseases. Overall, 90-day mortality was 19.7%, reaching 29% excluding cutaneous KS.
Implications: HHV-8 related diseases after SOT are relatively uncommon, but associated with high mortality rates. Standardized management protocols for HHV-8 diseases are needed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cmi.2025.07.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HIV-Associated Multicentric Castleman Disease with Kaposi Sarcoma: A Case Report with 120-Week Follow-Up of HHV-8 After Remission.
J Infect Chemother
September 2025
AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan; Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
HIV-associated multicentric Castleman disease (HIV-MCD) is a rare, life-threatening lymphoproliferative disorder featuring systemic inflammation and marked lymphadenopathy. HIV-MCD is characterized by a human herpesvirus-8 (HHV-8) infection, with an increasing incidence despite advances in antiretroviral therapy (ART). Although HHV-8 viremia is a recognized indicator of disease recurrence, the necessity of intervention for low-level viremia reactivation remains unclear.
View Article and Find Full Text PDFEstablishment and Quantification of De Novo Lytic Infection by Cell-free Kaposi's Sarcoma-Associated Herpesvirus.
J Vis Exp
August 2025
Program in Molecular and Cellular Oncogenesis, The Wistar Institute;
Kaposi's sarcoma-associated herpesvirus (KSHV), a gammaherpesvirus implicated in multiple human malignancies, can undergo lytic replication during primary infection, a process that contributes to viral dissemination, immune evasion, and disease pathogenesis. However, the lack of robust in vitro systems for de novo lytic infection has limited insights into early infection events. Here, we present a tractable protocol that employs human colorectal cancer HCT 116 cells as targets for infection with cell-free virions derived from KSHV bacterial artificial chromosome 16 (BAC16)-reactivated iSLK producer cells.
View Article and Find Full Text PDFAssessment of γ-herpesvirus infection dynamics in non-hospitalised people living with HIV during the COVID-19 pandemic in South Africa.
Virology
August 2025
International Centre for Genetic Engineering and Biotechnology (ICGEB), Cape Town 7925, South Africa; Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town, 7925, South Africa; Division of Medical Biochemistry and Structural Biol
Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) are oncogenic human γ-herpesviruses highly prevalent in Sub-Saharan Africa. Both establish latent early-life infections, with intermittent lytic reactivations, often triggered by viral co-infections, particularly in immunocompromised individuals. In this retrospective observational cross-sectional sub-study, we leveraged a cohort of 407 non-hospitalised people living with HIV (PLWH) attending antiretroviral therapy services in South Africa during the COVID-19 pandemic, with previously reported increased reactivation of KSHV upon SARS-CoV-2 exposure, particularly in COVID-19 unvaccinated individuals (Lambarey et al.
View Article and Find Full Text PDFInvestigation of human herpesvirus 8 & Leishmania species in malignant skin tumours, psoriasis, actinic keratoses, & seborrheic keratoses: A single-center experience from Ankara, Turkey.
Indian J Med Res
May 2025
Department of Pathology, Ministry of Health, Ankara Etlik City Hospital, Ankara, Turkey.
Background & objectives The role of human herpesvirus-8 (HHV-8) and Leishmania species in the aetiology of malignant skin tumours and proliferative skin diseases remains a topic of debate. This study aims to analyse formalin-fixed, paraffin-embedded (FFPE) skin biopsy samples using polymerase chain reaction (PCR) to determine whether skin lesions caused by HHV-8 and Leishmania spp. resemble malignant and proliferative skin diseases and assess the role of these pathogens in disease aetiology.
View Article and Find Full Text PDFOncogenic Mechanisms of Kaposi's Sarcoma-Associated Herpesvirus on Cell Metabolism and Cell Transformation.
J Med Virol
August 2025
Florida Research and Innovation Center, Cleveland Clinic, Port St. Lucie, Florida, USA.
Kaposi's sarcoma-associated herpesvirus (KSHV) is a human double-stranded DNA virus that is responsible for the development of Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), multicentric Castleman's disease (MCD), and KSHV inflammatory cytokine syndrome (KICS). KSHV infection manipulates distinct cellular proteins and signaling pathways, resulting in immune escape, cell death inhibition, infinite cell growth, and cancer formation. Current treatments for KSHV-associated cancers are limited to conventional strategies targeting nonviral cancers which encounter limited efficacy and drug resistance.
View Article and Find Full Text PDF